News
BioMarin submits NDA to FDA for vosoritide to treat children with achondroplasia.
BioMarin Pharmaceutical Inc. announced that it has submitted a New Drug Application (NDA) to the FDA for vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP) for children with achondroplasia, the most common form of disproportionate short stature in humans.
BioMarin recently announced that the European Medicines Agency (EMA) validated the Company's Marketing Authorization Application (MAA) for vosoritide on 13 August, 2020.
Condition: Achondroplasia
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins